10x Genomics, Inc. (TXG) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2025. 10x Genomics, Inc. is a life sciences technology company providing integrated research solutions, including Chromium instruments, Spatial instruments (Visium CytAssist and Xenium Analyzer), and proprietary consumables. The company operates as a single segment and is headquartered in Pleasanton, California.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $172.9 million | $153.1 million | $327.8 million | $294.1 million |
| Products & Services Revenue | $145.2 million | $153.0 million | $283.0 million | $294.0 million |
| License & Royalty Revenue | $27.8 million | $0.1 million | $44.8 million | $0.1 million |
| Gross Profit | $125.1 million | $104.2 million | $230.5 million | $197.1 million |
| Gross Margin | 72% | 68% | 70% | 67% |
| Net Income (Loss) | $34.5 million | ($37.9 million) | $0.2 million | ($97.8 million) |
| Diluted EPS | $0.28 | ($0.32) | $0.00 | ($0.82) |
| Cash & Marketable Securities | $447.3 million (as of June 30, 2025) | |||
| Operating Cash Flow (YTD) | $52.1 million | ($8.2 million) |
Material Changes vs. Prior Period
- Revenue Composition: Total revenue increased 13% QoQ and 11% YoY, driven almost entirely by License and Royalty Revenue ($27.8M in Q2 2025 vs. $0.1M in Q2 2024). This was due to settlements with Vizgen and Bruker.
- Core Business Decline: Products and Services revenue decreased 5% QoQ and 4% YoY. Instrument revenue fell 39% QoQ and 41% YoY, while Consumables revenue remained relatively flat (-1% QoQ, +2% YoY).
- Profitability: The company reported a net income of $34.5 million in Q2 2025, a significant turnaround from a net loss of $37.9 million in the prior year quarter. This was primarily due to a $40.7 million Gain on Settlement recorded in operating expenses related to the Bruker litigation resolution.
- Operating Expenses: Total operating expenses decreased 35% QoQ and 20% YoY, largely due to the aforementioned gain on settlement. Excluding the gain, R&D and SG&A expenses were reduced through a workforce reduction (approx. 8% of global workforce) and lower legal costs.
- Liquidity: Cash and cash equivalents increased to $397.7 million, with total liquid assets (including marketable securities) at $447.3 million.
Guidance, Outlook, and Risks
- Outlook: Management expects revenues, excluding the impact of license and royalty revenue, to slightly decline sequentially in Q3 2025. Gross margins are expected to fluctuate due to the non-recurring nature of the license revenue and changes in product mix.
- Cost Reduction: Operating expenses are expected to trend lower in 2025 following the May 2025 reduction in force and planned reductions in non-headcount expenses.
- Acquisition: On August 7, 2025 (subsequent event), the company entered a definitive agreement to acquire Scale Biosciences, Inc. for $30 million in upfront cash and stock, plus contingent consideration.
- Legal Proceedings:
- Resolved: Litigation with Vizgen (settled Feb 2025) and Bruker (settled May 2025) has been resolved with significant financial benefits.
- Ongoing: Litigation against Parse Biosciences continues, with a permanent injunction granted for certain patents, though trial is stayed pending appeals on other patents. Litigation against Curio Bioscience is ongoing, with a permanent injunction granted in Europe (UPC) but trial scheduled for May 2026 in the U.S.
- Risks: The company maintains an accumulated deficit of $1.5 billion and expects to continue incurring operating losses in the near term. Liquidity depends on cash generation and potential future financing.
Investor Verification Checklist
- Sustainability of Profitability: Verify if the Q2 net income is sustainable without the one-time $49.9 million gain on settlement (Vizgen and Bruker) and $44.8 million in license revenue.
- Core Revenue Trends: Confirm the trajectory of "Products and Services" revenue, which declined 5% QoQ, specifically the 39% drop in instrument sales.
- Restructuring Impact: Assess the long-term impact of the 8% workforce reduction on R&D capabilities and future product development.
- Acquisition Integration: Review the terms and strategic fit of the Scale Biosciences acquisition announced in August 2025.
- Legal Contingencies: Monitor the status of the Parse and Curio litigation, particularly the appeals regarding patent validity which could impact future royalty streams or market exclusivity.